Aquestive Therapeutics (NASDAQ:AQST) Director Julie Krop Sells 25,000 Shares of Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Director Julie Krop sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the transaction, the director owned 25,000 shares of the company’s stock, valued at approximately $125,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ AQST opened at $5.00 on Thursday. The company has a market capitalization of $626.62 million, a PE ratio of -8.19 and a beta of 1.46. The company’s fifty day moving average price is $4.22 and its 200 day moving average price is $4.40. Aquestive Therapeutics, Inc. has a 1 year low of $2.93 and a 1 year high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. The firm had revenue of $14.45 million during the quarter, compared to analyst estimates of $10.90 million. On average, equities analysts expect that Aquestive Therapeutics, Inc. will post -0.41 EPS for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Institutional investors have recently bought and sold shares of the company. Arete Wealth Advisors LLC acquired a new position in shares of Aquestive Therapeutics during the first quarter valued at approximately $504,000. Bank of America Corp DE lifted its position in shares of Aquestive Therapeutics by 99.2% in the first quarter. Bank of America Corp DE now owns 2,405,050 shares of the company’s stock valued at $9,981,000 after acquiring an additional 1,197,459 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Aquestive Therapeutics by 103.9% in the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after acquiring an additional 264,000 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Aquestive Therapeutics by 133.0% in the first quarter. Royal Bank of Canada now owns 28,951 shares of the company’s stock worth $120,000 after acquiring an additional 16,525 shares during the last quarter. Finally, Quantinno Capital Management LP increased its position in shares of Aquestive Therapeutics by 52.8% during the first quarter. Quantinno Capital Management LP now owns 18,014 shares of the company’s stock worth $75,000 after purchasing an additional 6,221 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on AQST. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Monday, April 20th. Finally, Oppenheimer started coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $8.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $8.50.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.